Allianz Asset Management
CRSP icon

Allianz Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Allianz Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,534
Closed -$359K – 2010
2025
Q3 		$359K Buy
+5,534
New +$318K ﹤0.01% 1902
2024
Q3 		– Sell
-3,800
Closed -$205K – 2194
2024
Q2 		$205K Sell
3,800
-11,992
-76% -$694K ﹤0.01% 2030
2024
Q1 		$1.08M Buy
15,792
+451
+3% +$32.3K ﹤0.01% 1387
2023
Q4 		$960K Buy
15,341
+1,300
+9% +$71.9K ﹤0.01% 1614
2023
Q3 		$637K Sell
14,041
-41,722
-75% -$2.15M ﹤0.01% 1844
2023
Q2 		$3.13M Buy
55,763
+1,712
+3% +$97.1K 0.01% 1080
2023
Q1 		$2.44M Buy
54,051
+3,499
+7% +$170K ﹤0.01% 1292
2022
Q4 		$2.05M Buy
50,552
+209
+0.4% +$11.1K ﹤0.01% 1277
2022
Q3 		$3.29M Buy
50,343
+23,071
+85% +$1.67M 0.01% 1054
2022
Q2 		$1.66M Hold
27,272
– – ﹤0.01% 1488
2022
Q1 		$1.71M Sell
27,272
-15,865
-37% -$996K ﹤0.01% 1644
2021
Q4 		$3.28M Buy
43,137
+1,075
+3% +$93.9K ﹤0.01% 1408
2021
Q3 		$4.71M Sell
42,062
-24,186
-37% -$3.04M ﹤0.01% 1301
2021
Q2 		$10.7M Buy
66,248
+40,421
+157% +$4.92M 0.01% 828
2021
Q1 		$3.15M Buy
25,827
+3,763
+17% +$568K ﹤0.01% 1239
2020
Q4 		$3.38M Buy
+22,064
New +$2.61M ﹤0.01% 1164
2020
Q2 		– Sell
-82,123
Closed -$3.48M – 2412
2020
Q1 		$3.48M Buy
82,123
+48,316
+143% +$2.49M ﹤0.01% 1313
2019
Q4 		$2.06M Sell
33,807
-5,869
-15% -$320K ﹤0.01% 1861
2019
Q3 		$1.64M Sell
39,676
-20,594
-34% -$984K ﹤0.01% 1915
2019
Q2 		$2.84M Sell
60,270
-19,246
-24% -$769K ﹤0.01% 1750
2019
Q1 		$2.84M Buy
79,516
+17,164
+28% +$593K ﹤0.01% 1698
2018
Q4 		$1.75M Buy
62,352
+2,527
+4% +$87.8K ﹤0.01% 1812
2018
Q3 		$2.65M Sell
59,825
-65,632
-52% -$3.44M ﹤0.01% 1834
2018
Q2 		$7.37M Sell
125,457
-107,287
-46% -$6.11M 0.01% 1375
2018
Q1 		$10.6M Buy
232,744
+684
+0.3% +$28.2K 0.01% 1225
2017
Q4 		$5.45M Buy
232,060
+98,690
+74% +$1.88M ﹤0.01% 1584
2017
Q3 		$2.38M Buy
+133,370
New +$2.42M ﹤0.01% 1946

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $602M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allianz Asset Management's CRSP Position: Q4 2025 in Review

Allianz Asset Management sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 5,534 shares — an estimated $359K sold.

Allianz Asset Management first reported a position in CRSP in Q3 2017 and held it in 27 quarters. The position peaked at $10.7M in Q2 2021. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Allianz Asset Management reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Allianz Asset Management sold 5,534 CRISPR Therapeutics shares in Q4 2025, an estimated $359K.
  • Allianz Asset Management first reported a position in CRISPR Therapeutics in Q3 2017 and held it in 27 quarters.
  • Allianz Asset Management's CRISPR Therapeutics position peaked at $10.7M in Q2 2021.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Allianz Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.